| Evolving treatment strategies for the management of type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 22205062 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
ABSTRACT:: It is well known that improved metabolic control significantly reduces both micro- and macrovascular complications in diabetes. As it relates to specific treatment of type 2 diabetes mellitus, clinicians have traditionally initiated lifestyle intervention and progressed therapy using various drug treatments first as monotherapy and then as combination therapy throughout the course of the disease. This "stepwise" strategy has not always achieved the desired outcome of normal glycemic control; consequently, several clinical problems, such as hypoglycemia, weight gain and postprandial hyperglycemia, persist. However, new therapies that improve glycemic control and have favorable effects to address the unmet clinical problems have recently been developed or are still in development. These therapies include 2 classes of incretin-directed therapy, the dipeptidyl peptidase-4 inhibitors and the glucagon-like peptide-1 agonists, which help restore physiologic levels and activity of the incretin glucagon-like peptide-1. Also in development are additional therapies that have effects on the kidney to promote glucose excretion. These therapies are proposed to treat the key metabolic abnormalities associated with type 2 diabetes mellitus and minimize the side effects noted with conventional therapies. |
| | |
Authors:
|
William T Cefalu |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of the medical sciences Volume: 343 ISSN: 1538-2990 ISO Abbreviation: Am. J. Med. Sci. Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-12-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370506 Medline TA: Am J Med Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 21-6 Citation Subset: AIM; IM |
Affiliation:
|
From the Joint Program on Diabetes, Endocrinology and Metabolism, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, and Louisiana State University Heath Sciences Center School of Medicine, New Orleans, Louisiana. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Benefits and risks for intensive glycemic control in patients with diabetes mellitus.
Next Document: Influence of 1-D silica nanotubes as drug adsorbent on release behaviors of tulobuterol-loaded porou...